Light Chain Bioscience at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Light Chain Bioscience brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on tumour-selective CD47 targeting for platinum-resistant ovarian cancer, in the track on engineering next-generation bispecific antibodies.

OrganizationPEGS Europe 2026 Attendance
Light Chain Bioscience
Plan-les-Ouates, Switzerland
Biotech
NovImmune brand developing kappa-lambda bispecific antibodies, including tumour-selective CD47 programmes.
Chair
Thu Nov 19
8:25am–8:30am
Chairperson's Remarks
Engineering the Next Generation of Bispecific Antibodies
Chair
Thu Nov 19
10:44am–10:45am
Chairperson's Remarks
Engineering the Next Generation of Bispecific Antibodies
Talk
Thu Nov 19
2:05pm–2:35pm
Tumour-Selective CD47 Targeting for the Treatment of Platinum-Resistant Ovarian Cancer
Engineering the Next Generation of Bispecific Antibodies

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Light Chain Bioscience

Tell us what you sell and we’ll find the people at Light Chain Bioscience most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction